Drugs / VSA003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05851066 | Jun 2023 → May 2024 | familial hypercholesterolemia, hypertriglyceridemia | Visirna Therapeutics HK Limited | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06712771 | Nov 2024 → Dec 2025 overdue | homozygous familial hypercholesterolemia | Visirna Therapeutics HK Limited | Active not recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-07 | Visirna Therapeutics HK Limited | Visirna Completes Enrollment of China Phase III Study of VSA003 for Treatment of Homozygous Familial Hypercholesterolemia (HoFH) visirna.com ↗ |
| 2024-12-18 | Visirna Therapeutics HK Limited | Visirna Completes Dosing of the First Patient in China Phase III Study of VSA003 for Treatment of Homozygous Familial Hypercholesterolemia visirna.com ↗ |
| 2024-01-29 | Visirna Therapeutics HK Limited | Visirna Announces Breakthrough Therapy Designation Granted for VSA003 for Treatment of Patients with Homozygous Familial Hypercholesterolemia (HoFH) visirna.com ↗ |
| 2023-07-07 | Visirna Therapeutics HK Limited | Visirna Announces Dosing of the First Subjects in China Phase I Study of VSA003 visirna.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSA003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05851066 ↗ |
| Route | Subcutaneous | “by subcutaneous (sc) injections” NCT05851066 ↗ |
| Target | ANGPTL3 | “an RNAi-based therapeutic targeting ANGPTL3” NCT06712771 ↗ |